Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis.
Wang S et al. Cell Death Dis. 2017 Sep 21;8(9):e3058. doi: 10.1038/cddis.2017.450.
The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma.
Mroczek S et al. Nat Commun. 2017 Sep 20;8(1):619. doi: 10.1038/s41467-017-00578-5.
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Dorasamy MS et al. J Cancer. 2017 Sep 5;8(15):3086-3098. doi: 10.7150/jca.14835. eCollection 2017.
Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.
Pan J et al. Oncol Lett. 2017 Sep;14(3):2657-2662. doi: 10.3892/ol.2017.6528. Epub 2017 Jul 7.
Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels.
Jian Y et al. Oncol Lett. 2017 Sep;14(3):3243-3248. doi: 10.3892/ol.2017.6502. Epub 2017 Jun 30.
Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions.
Clemens J et al. Oncol Lett. 2017 Sep;14(3):3185-3192. doi: 10.3892/ol.2017.6560. Epub 2017 Jul 8.
Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma.
Chang X et al. Int J Mol Sci. 2017 Sep 17;18(9). pii: E1999. doi: 10.3390/ijms18091999.
14-3-3ζ binds the proteasome, limits proteolytic function, and enhances sensitivity to proteasome inhibitors.
Gu Y et al. Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.288. [Epub ahead of print].
1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Liu YM et al. Eur J Med Chem. 2017 Sep 6;140:84-91. doi: 10.1016/j.ejmech.2017.09.011. [Epub ahead of print].
The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Iriyama N et al. Leuk Lymphoma. 2017 Sep 18:1-12. doi: 10.1080/10428194.2017.1376741. [Epub ahead of print].
Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients.
Blancas-Mejía LM et al. Biophys Chem. 2017 Sep 1. pii: S0301-4622(17)30307-1. doi: 10.1016/j.bpc.2017.08.011. [Epub ahead of print].
Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.
Lee J et al. Bioorg Med Chem Lett. 2017 Sep 6. pii: S0960-894X(17)30889-2. doi: 10.1016/j.bmcl.2017.09.002. [Epub ahead of print].
Physiologically-based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions.
Einolf HJ et al. Drug Metab Dispos. 2017 Sep 14. pii: dmd.117.076851. doi: 10.1124/dmd.117.076851. [Epub ahead of print].
MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting Hedgehog signaling.
Tang B et al. Int J Cancer. 2017 Sep 14. doi: 10.1002/ijc.31041. [Epub ahead of print].
Extracellular S100A9 protein in bone marrow supports multiple myelomasurvival by stimulating angiogenesis and cytokine secretion.
De Veirman K et al. Cancer Immunol Res. 2017 Sep 13. pii: canimm.0192.2017. doi: 10.1158/2326-6066.CIR-17-0192. [Epub ahead of print].
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li N et al. Cell Rep. 2017 Sep 12;20(11):2556-2564. doi: 10.1016/j.celrep.2017.08.062.
Triptolide blocks the STAT3 signaling pathway through induction of protein tyrosine phosphatase SHP-1 in multiple myeloma cells.
Kim JH et al. Int J Mol Med. 2017 Sep 6. doi: 10.3892/ijmm.2017.3122. [Epub ahead of print].
ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Pro-Survival Autophagy.
Zhang H et al. Oncol Res. 2017 Sep 11. doi: 10.3727/096504017X15049221237147. [Epub ahead of print].
SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture.
Arhoma A et al. Exp Cell Res. 2017 Sep 8. pii: S0014-4827(17)30488-3. doi: 10.1016/j.yexcr.2017.09.012. [Epub ahead of print].
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.
Moschetta M et al. Curr Osteoporos Rep. 2017 Sep 9. doi: 10.1007/s11914-017-0399-3. [Epub ahead of print].
Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma.
Suto Y et al. Bioorg Med Chem Lett. 2017 Oct 1;27(19):4558-4563. doi: 10.1016/j.bmcl.2017.08.054. Epub 2017 Aug 30.
The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of Multiple Myeloma.
Le Moigne R et al. Mol Cancer Ther. 2017 Sep 6. pii: molcanther.0233.2017. doi: 10.1158/1535-7163.MCT-17-0233. [Epub ahead of print].
Silencing of augmenter of liver regeneration inhibited cell proliferation and triggered apoptosis in U266 human multiple myeloma cells.
Zeng HQ et al. Braz J Med Biol Res. 2017 Aug 31;50(10):e6139. doi: 10.1590/1414-431X20176139.
Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma.
Atanackovic D et al. Curr Cancer Drug Targets. 2017 Sep 6. doi: 10.2174/1568009617666170906170348. [Epub ahead of print].
A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myelomacells via G2/M cell-cycle arrest.
Aida S et al. Biochem Biophys Res Commun. 2017 Sep 1. pii: S0006-291X(17)31733-3. doi: 10.1016/j.bbrc.2017.08.159. [Epub ahead of print].
The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
Tu YS et al. Neoplasia. 2017 Aug 29;19(10):772-780. doi: 10.1016/j.neo.2017.07.009. [Epub ahead of print].
SIRT1/HERC4 Locus Associated with Bisphosphonate-Induced Osteonecrosis of the Jaw: An Exome-Wide Association Analysis.
Yang G et al. J Bone Miner Res. 2017 Aug 30. doi: 10.1002/jbmr.3285. [Epub ahead of print].
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Hernández-García S et al. Haematologica. 2017 Aug 31. pii: haematol.2017.168666. doi: 10.3324/haematol.2017.168666. [Epub ahead of print].
The ceramide pathway is involved in the survival, apoptosis and exosome functions of human multiple myeloma cells in vitro.
Cheng Q et al. Acta Pharmacol Sin. 2017 Aug 31. doi: 10.1038/aps.2017.118. [Epub ahead of print].
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Zaal EA et al. Cancer Metab. 2017 Aug 29;5:7. doi: 10.1186/s40170-017-0169-9. eCollection 2017.
HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1.
Vandyke K et al. Cancer Res. 2017 Aug 30. pii: canres.0115.2017. doi: 10.1158/0008-5472.CAN-17-0115. [Epub ahead of print].
Epinephrine Stimulates Cell Proliferation and Induces Chemoresistance in Myeloma Cells through the β-Adrenoreceptor in vitro.
Liu Y et al. Acta Haematol. 2017;138(2):103-110. doi: 10.1159/000478517. Epub 2017 Aug 29.
Ex Vivo Induction of Multiple Myeloma-specific Immune Responses by Monocyte-derived Dendritic Cells Following Stimulation by Whole-tumor Antigen of Autologous Myeloma Cells.
Vasileiou S et al. J Immunother. 2017 Sep;40(7):253-264. doi: 10.1097/CJI.0000000000000182.
RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the Wnt signaling pathway.
Cheng Q et al. Clin Exp Pharmacol Physiol. 2017 Sep 25. doi: 10.1111/1440-1681.12859. [Epub ahead of print].
Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells.
Issa ME et al. Front Pharmacol. 2017 Sep 8;8:610. doi: 10.3389/fphar.2017.00610. eCollection 2017.
Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.
Zhang Y et al. Oncotarget. 2017 Aug 1;8(35):59476-59491. doi: 10.18632/oncotarget.19761. eCollection 2017 Aug 29.